Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

No studies found 2 · 40%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 60%Moderate 0 · 0%High 0 · 0%

Rate of vasomotor symptoms ‐ · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rate of vasomotor symptoms ‐ · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rate of vasomotor symptoms ‐ · patients with uterine fibroids

GnRH‐a + tibolone showed no clear difference in rate of vasomotor symptoms ‐ compared with gnRH‐a ± placebo (low certainty).

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
RR 0.38 [0.14, 1.02]
1 study · 20 participants
Low

Rate of vasomotor symptoms ‐ · patients with uterine fibroids

GnRH‐a + ipriflavone showed no clear difference in rate of vasomotor symptoms ‐ compared with gnRH‐a ± placebo (low certainty).

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
RR 0.67 [0.44, 1.02]
1 study · 95 participants
Low

Rate of vasomotor symptoms ‐ · patients with uterine fibroids

GnRH‐a + medroxyprogesterone acetate may leads to lower rate of vasomotor symptoms ‐ compared with gnRH‐a ± placebo (low certainty).

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
RR 0.13 [0.02, 0.84]
1 study · 16 participants
Low